Why emodepside formulation matters in dogs with resistant hookworms
A new American Journal of Veterinary Research study is sharpening the message around extra-label emodepside use in dogs: formulation matters, and the feline topical product should not be assumed to behave like the canine oral product used in Europe. In a 7-dog crossover pharmacokinetic study, investigators found that the FDA-approved feline topical emodepside/praziquantel solution, when given orally at 1 mg/kg, produced markedly higher emodepside absorption than the European canine modified-release tablet and failed bioequivalence testing. On the AVMA’s Veterinary Vertex podcast, the authors said the oral feline product produced about 3 times higher peak plasma concentrations and 2.4- to 2.8-times greater total systemic exposure than the canine tablet at the same dose. The same feline product, when applied topically, produced plasma concentrations 36- to 122-fold lower than oral administration, suggesting it may not be suitable for treating multianthelmintic drug-resistant hookworms in dogs. (pubmed.ncbi.nlm.nih.gov; veterinaryvertex.buzzsprout.com)
Why it matters: For veterinary professionals, this is a practical safety and stewardship story. Emodepside has emerged as a last-line option for suspected multidrug-resistant Ancylostoma caninum, but prior guidance already stressed careful in-clinic dosing, fecal egg count monitoring, and caution in dogs with MDR1 risk. The new data add a clearer warning: switching formulations or routes doesn’t just change convenience, it can materially change drug exposure, efficacy expectations, and toxicity risk. The podcast discussion also underscored a useful clinical reminder: emodepside belongs to the octadepsipeptide class and works through a different mechanism than other antiparasitics currently on the market, which helps explain why it has drawn attention in resistant hookworm cases. (assets.takeshape.io; veterinaryvertex.buzzsprout.com)
What to watch: Expect this paper to influence how parasitologists and frontline clinicians discuss extra-label emodepside protocols, especially around case selection, informed consent, and whether additional canine-specific safety and dosing studies follow. It may also reinforce that “bioequivalent” is not a casual assumption: as discussed by the study authors, the FDA standard means products must be comparable in both the rate and extent of absorption, and these formulations did not meet that bar. (pubmed.ncbi.nlm.nih.gov; veterinaryvertex.buzzsprout.com)